Autres langues Ipsen

Actions

IPN

FR0010259150

Produits pharmaceutiques

Marché Fermé - Euronext Paris Autres places de cotation 17:55:00 17/07/2026			Après clôture 21:59:59
161,40 ^EUR	+2,22%		161,40	0,00%

14/07	Où l'intelligence artificielle mènera-t-elle l'industrie pharmaceutique à long terme ?
13/07	BlackRock dépasse les 5% du capital d'Ipsen

Autres langues

15/07	IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026
14/07	Where would AI lead Pharma in the long run?
13/07	Ipsen : IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study
10/07	Ipsen - Dysport is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine
09/07	Afternoon Meeting: Wall Street ignora las alarmas
09/07	Wall Street Ignores the Sirens
09/07	Ipsen Reports Positive Topline Phase III Results for Dysport in Both Episodic and Chronic Migraine
09/07	Öl hält die Märkte in Atem
09/07	Oil keeps markets on edge
09/07	Ipsen's Migraine Treatment Meets Primary Endpoints in Late-stage Trial
09/07	Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
07/07	Ipsen - Half year statement - 2026 06 30
07/07	AlphaValue/Baader Europe Cuts Ipsen Price Target Amid Future Patent Expiries, Mid-term Risks
06/07	IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026
06/07	IPSEN : Reassessing mid-term risks
03/07	IPSEN - Buy-back programme - Art 5 of MAR - Week 26- 2026
02/07	Ipsen buys Schroders Capital Global investee
01/07	Health Care Up on AI Rotation - Health Care Roundup
01/07	Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S. -- Update
01/07	Deals of the day-Mergers and acquisitions
01/07	Galderma-Aktien nach Zulassungsrückschlag in USA auf Verkaufszetteln
01/07	Ipsen to Acquire Memo Therapeutics in Up to EUR700 Million Deal
01/07	French biotech Ipsen to buy Memo Therapeutics for $230 million upfront
01/07	Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01/07	Ipsen S.A. entered into a definitive share purchase agreement to acquire Memo Therapeutics AG for over ?700 million.